AMIVAS Launches Artesunate AMIVAS in Europe
AMIVAS Ireland Ltd (AMIVAS), a dedicated biopharmaceutical organization, has announced the launch of Artesunate AMIVAS, a significant advancement in the treatment of severe malaria available across Europe and the U.K. This groundbreaking product is the first of its kind, receiving formal licensing and approval to provide essential care for severe malaria patients.
Importance of Artesunate AMIVAS
Artesunate AMIVAS comes in a 110-milligram format, specifically a powder and solvent that forms an injectable solution. This highly anticipated product is crucial as severe malaria affects around 1,250 European travelers annually, highlighting the importance of quick access to effective treatment in emergency situations.
Availability of Artesunate AMIVAS
The product is available through Nordic Prime, a distributor operating in Denmark, Finland, Sweden, and Norway. The ability to easily order and administer Artesunate AMIVAS in these countries represents a positive step forward in public health and medicinal developments.
The Mission Behind AMIVAS
Laura Walsh, the Operations Director at AMIVAS, emphasized that this launch is not just a business milestone, but a vital advancement for travelers and military personnel who may be exposed to malaria-endemic regions. With Artesunate AMIVAS, healthcare professionals can confidently treat adults and children diagnosed with severe malaria, knowing they have access to a proven solution.
Historical Achievements of AMIVAS
Sean Power, AMIVAS Director, expressed satisfaction regarding the launch, mentioning its previous success in the United States. He explained that their mission revolves around providing safe and effective medical solutions that can significantly enhance the lives of patients in need.
Regulatory Approvals
Artesunate AMIVAS has a solid foundation, having received approval from the U.S. Food and Drug Administration in 2020. Moreover, the European Union Commission also awarded AMIVAS Ireland the necessary permissions to commercialize the product in the EU and EEA, demonstrating a commitment to healthcare excellence.
Understanding Severe Malaria
Malaria, caused by Plasmodium parasites and transmitted via mosquito bites, remains a significant health concern for global populations. With approximately 400,000 deaths annually and a resurgence of the disease in Europe, the necessity for a licensed treatment like Artesunate AMIVAS is clearer than ever. The disease notably impacts pregnant women, infants, and those with low immunity, highlighting the urgency of effective treatments.
Role of Artesunate in Treatment
For over two decades, intravenous artesunate has led as the standard treatment for severe malaria. Its proven effectiveness over conventional medicines such as quinine, with reduced mortality risks, showcases why Artesunate AMIVAS is a vital addition to healthcare providers’ arsenals.
AMIVAS's Commitment to Patient Care
Headquartered in Nassau, Delaware, AMIVAS aims to redefine patient care in the realm of infectious diseases. The company emerged from the need for regulated manufacturing and distribution of artesunate after the market faced gaps following the discontinuation of quinidine gluconate.
Future Perspectives
By leveraging its expertise and innovation, AMIVAS is set on becoming a leader in infectious disease treatments, ensuring patients receive quality care and rapid access to essential medicines. Their focus remains on scientific discovery, positioning them at the forefront of healthcare advancements.
Frequently Asked Questions
What is Artesunate AMIVAS?
Artesunate AMIVAS is a licensed injectable treatment for severe malaria, manufactured and approved for safe use in Europe and the U.K.
Who can benefit from Artesunate AMIVAS?
This treatment is designed for anyone at risk of severe malaria, including travelers and military personnel in endemic regions.
How does Artesunate compare to other treatments?
Artesunate AMIVAS has been shown to reduce mortality rates more effectively than traditional treatments like quinine.
Where can Artesunate AMIVAS be ordered?
It is available via Nordic Prime in several Nordic countries, providing convenient access for European patients.
What are the risks of severe malaria?
If untreated, severe malaria has a mortality rate that can approach 100 percent, emphasizing the critical need for rapid treatment options like Artesunate AMIVAS.
